Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
The overview and definition of myelofibrosis provides essential insight for patients and families confronting this rare blood disorder. Myelofibrosis is a type of chronic myeloproliferative neoplasm that originates in the bone marrow, leading to scar tissue formation and impaired blood cell production. This page is designed for international patients seeking clear, medically accurate information about the disease, its progression, and the comprehensive care options available at Liv Hospital. According to recent hematology registries, approximately 1,500 new cases are diagnosed worldwide each year, underscoring the importance of early recognition and specialized treatment.
In the following sections, we will explore the disease’s underlying mechanisms, typical clinical presentation, diagnostic pathways, staging systems, therapeutic strategies, and practical advice for living well with myelofibrosis. The content reflects the expertise of Liv Hospital’s multidisciplinary hematology team, which combines state‑of‑the‑art technology with compassionate, 360‑degree international patient support.
Myelofibrosis, also known as primary myelofibrosis (PMF) when it arises without a preceding condition, is a chronic bone‑marrow disorder characterized by the excessive deposition of fibrous tissue. This fibrotic transformation replaces the normal marrow environment, forcing blood‑forming cells to migrate to the spleen and liver—a process called extramedullary hematopoiesis.
Key pathological features include:
The disease typically presents in adults between 50 and 70 years of age, but younger patients can be affected, especially when genetic mutations such as JAK2, CALR, or MPL are present. Understanding the overview and definition of myelofibrosis is the first step toward appropriate management and improved quality of life.
Myelofibrosis is not caused by lifestyle choices; rather, it emerges from genetic and molecular abnormalities within hematopoietic stem cells. The most common driver mutations include:
Additional risk factors that may influence disease onset or progression include:
Age > 60 years
Male gender (slightly higher incidence)
Family history of myeloproliferative neoplasms
Exposure to ionizing radiation (rare)
While the exact trigger for the clonal mutation remains unclear, ongoing research at leading centers—including Liv Hospital—investigates epigenetic changes and environmental contributors that could refine prevention strategies.
Patients often experience a constellation of constitutional and organ‑specific symptoms. The most frequently reported manifestations are:
Because these signs overlap with other hematologic conditions, a thorough diagnostic work‑up is essential. The diagnostic algorithm typically includes:
According to the World Health Organization (WHO) criteria, a diagnosis of primary myelofibrosis requires meeting major and minor criteria that incorporate the above findings. Early detection enables timely therapeutic intervention, which can mitigate symptom burden and potentially alter disease trajectory.
Staging myelofibrosis helps clinicians estimate survival and select appropriate treatment intensity. The most widely used prognostic models are the International Prognostic Scoring System (IPSS) for newly diagnosed patients and the Dynamic IPSS (DIPSS‑plus) for those undergoing follow‑up.
Factors considered include age > 65 years, hemoglobin < 10 g/dL, leukocyte count > 25 × 10⁹/L, circulating blasts ≥ 1%, and constitutional symptoms. The DIPSS‑plus model adds karyotype abnormalities, platelet count < 100 × 10⁹/L, and transfusion dependence, providing a more nuanced risk assessment for patients already under treatment.
Accurate staging is vital for determining eligibility for curative options such as allogeneic stem‑cell transplantation versus disease‑modifying therapies.
Therapeutic goals in myelofibrosis focus on symptom control, reduction of splenomegaly, prevention of disease progression, and, when feasible, cure. Treatment selection is guided by risk category, symptom severity, and patient comorbidities.
Current standard‑of‑care modalities include:
Emerging therapies under investigation at leading research centers, including Liv Hospital’s hematology department, comprise:
Clinical trials are actively recruiting, offering patients access to cutting‑edge treatments while contributing to the global knowledge base.
Beyond medical interventions, patients benefit from comprehensive supportive services that address physical, emotional, and logistical challenges. Key components of a holistic care plan include:
Liv Hospital’s international patient program provides dedicated case managers who arrange transportation, accommodation, and language support, allowing patients to focus on recovery rather than logistics. Engaging in regular physical activity, adhering to prescribed medications, and maintaining open communication with the care team are proven strategies for enhancing quality of life.
Liv Hospital combines JCI accreditation, cutting‑edge technology, and a multilingual team to deliver world‑class hematology care to patients from around the globe. Our specialists have extensive experience in managing myelofibrosis, offering personalized treatment plans that incorporate the latest clinical trial options. International patients receive end‑to‑end support, including visa assistance, airport transfers, interpreter services, and comfortable accommodation near our state‑of‑the‑art facilities. Trust Liv Hospital for compassionate, evidence‑based care that prioritizes your health and peace of mind.
Ready to take the next step in your myelofibrosis journey? Contact Liv Hospital’s international patient office today to schedule a comprehensive consultation and explore personalized treatment options.
Our team is here to guide you every step of the way, from initial assessment to ongoing support.
Liv Hospital Vadistanbul
Prof. MD. Itır Şirinoğlu Demiriz
Hematology
Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan
Pediatric Hematology and Oncology
Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun
Pediatric Hematology and Oncology
Liv Hospital Ankara
Assoc. Prof. MD. Ramazan Öcal
Hematology
Liv Hospital Ankara
Prof. MD. Meral Beksaç
Hematology
Liv Hospital Ankara
Prof. MD. Oral Nevruz
Hematology
Liv Hospital Gaziantep
Assoc. Prof. MD. Fadime Ersoy Dursun
Hematology
Spec. MD. Ceyda Aslan
Hematology
Spec. MD. Elmir İsrafilov
Hematology
Spec. MD. Minure Abışova Eliyeva
Hematology
Liv Hospital Ulus + Liv Hospital Bahçeşehir
Prof. MD. Mehmet Hilmi Doğu
Hematology
Send us all your questions or requests, and our expert team will assist you.
Myelofibrosis is not caused by lifestyle choices. The most frequent driver mutations are JAK2 V617F (≈50‑60% of cases), CALR exon 9 (≈20‑30%), and MPL W515L/K (≈5‑10%). These mutations activate the JAK‑STAT pathway, promoting uncontrolled cell growth and fibrosis. Additional risk factors that increase the likelihood of disease onset or faster progression are age over 60, male sex, a family history of myeloproliferative neoplasms, and, in rare instances, prior exposure to ionizing radiation. Ongoing research also explores epigenetic and environmental contributors.
Myelofibrosis is not caused by lifestyle choices. The most frequent driver mutations are JAK2 V617F (≈50‑60% of cases), CALR exon 9 (≈20‑30%), and MPL W515L/K (≈5‑10%). These mutations activate the JAK‑STAT pathway, promoting uncontrolled cell growth and fibrosis. Additional risk factors that increase the likelihood of disease onset or faster progression are age over 60, male sex, a family history of myeloproliferative neoplasms, and, in rare instances, prior exposure to ionizing radiation. Ongoing research also explores epigenetic and environmental contributors.
The diagnostic algorithm starts with a complete blood count that often shows anemia, leukocytosis, or thrombocytosis. A bone‑marrow biopsy evaluates the degree of fibrosis (reticulin to collagen) and cellularity. Molecular testing for JAK2, CALR, MPL, and other mutations confirms the clonal nature of the disease. Imaging (ultrasound or MRI) assesses spleen size. The WHO criteria combine major and minor findings to establish a diagnosis. Once diagnosed, clinicians apply the International Prognostic Scoring System (IPSS) for newly diagnosed patients or the Dynamic IPSS (DIPSS‑plus) for those under treatment, incorporating factors such as age, hemoglobin level, leukocyte count, circulating blasts, constitutional symptoms, karyotype, platelet count, and transfusion dependence to estimate survival and guide therapy.
The diagnostic algorithm starts with a complete blood count that often shows anemia, leukocytosis, or thrombocytosis. A bone‑marrow biopsy evaluates the degree of fibrosis (reticulin to collagen) and cellularity. Molecular testing for JAK2, CALR, MPL, and other mutations confirms the clonal nature of the disease. Imaging (ultrasound or MRI) assesses spleen size. The WHO criteria combine major and minor findings to establish a diagnosis. Once diagnosed, clinicians apply the International Prognostic Scoring System (IPSS) for newly diagnosed patients or the Dynamic IPSS (DIPSS‑plus) for those under treatment, incorporating factors such as age, hemoglobin level, leukocyte count, circulating blasts, constitutional symptoms, karyotype, platelet count, and transfusion dependence to estimate survival and guide therapy.
Treatment is individualized based on risk category, symptom burden, and comorbidities. JAK inhibitors such as ruxolitinib and fedratinib reduce spleen size and improve constitutional symptoms. Hydroxyurea can control leukocytosis and thrombocytosis, while immunomodulatory agents (thalidomide, lenalidomide) are used in select cases. Supportive measures—blood transfusions, erythropoiesis‑stimulating agents, bisphosphonates for bone pain, and vaccination—address complications. Allogeneic hematopoietic stem‑cell transplantation remains the only potentially curative option, reserved for high‑risk or younger patients. Emerging agents under investigation include momelotinib, pacritinib, combination regimens with BET or BCL‑2 inhibitors, and gene‑editing approaches targeting driver mutations.
Liv Hospital’s International Patient Program provides end‑to‑end support for patients traveling from abroad. Services include assistance with visa applications, coordinated airport pickups, multilingual interpreter availability, and comfortable lodging near the hospital. Dedicated case managers arrange appointments, ensure continuity of care, and facilitate participation in clinical trials. The hospital also offers psychosocial support groups, nutrition counseling, and regular monitoring of blood counts and organ function, aiming to improve quality of life while patients receive state‑of‑the‑art hematology care.
BlogHematologyApr 08, 2026Did you know that blood disorders affect millions of people worldwide, causing a wide range of health issue...
BlogHematologyApr 07, 2026Every year, over 1.8 million people in the United States get cancer. Hematology oncology is key in fighting...
BlogHematologyApr 06, 2026Pulmonary hemorrhage is a serious condition where blood enters the lung tissue and airways suddenly or over...
BlogHematologyApr 03, 2026Vitamin B12 and folic acid are key nutrients. They help keep red blood cells healthy, support nerve functio...
BlogHematologyApr 03, 2026Vitamin B is key for our health, helping with energy and brain function. At LivHospital, we know how import...
BlogHematologyApr 03, 2026Vitamin B12 and folate (vitamin B9) are essential nutrients for our nerves and for making red blood cells. ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 42 01